Cargando…

Plasma metabolomics of presymptomatic PSEN1‐H163Y mutation carriers: a pilot study

BACKGROUND AND OBJECTIVE: PSEN1‐H163Y carriers, at the presymptomatic stage, have reduced (18)FDG‐PET binding in the cerebrum of the brain (Scholl et al., Neurobiol Aging 32:1388–1399, 2011). This could imply dysfunctional energy metabolism in the brain. In this study, plasma of presymptomatic PSEN1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Natarajan, Karthick, Ullgren, Abbe, Khoshnood, Behzad, Johansson, Charlotte, Laffita‐Mesa, José M., Pannee, Josef, Zetterberg, Henrik, Blennow, Kaj, Graff, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951103/ https://www.ncbi.nlm.nih.gov/pubmed/33476461 http://dx.doi.org/10.1002/acn3.51296

Ejemplares similares

TBK1 haploinsufficiency results in changes in the K63-ubiquitination profiles in brain and fibroblasts from affected and presymptomatic mutation carriers
por: Khoshnood, Behzad, et al.
Publicado: (2021)

APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal‐dominant Alzheimer's disease
por: Almkvist, Ove, et al.
Publicado: (2022)

Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers
por: Remnestål, Julia, et al.
Publicado: (2020)

Single-cell multimodal analysis in a case with reduced penetrance of Progranulin-Frontotemporal Dementia
por: Natarajan, Karthick, et al.
Publicado: (2021)

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study
por: Thordardottir, Steinunn, et al.
Publicado: (2018)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
por: Rostgaard, Nina, et al.
Publicado: (2018)

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study
por: Bergström, Sofia, et al.
Publicado: (2021)

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
por: Weston, Philip S. J., et al.
Publicado: (2019)

Disease-related cortical thinning in presymptomatic granulin mutation carriers
por: Borrego-Écija, Sergi, et al.
Publicado: (2020)

The APOE ε4 Allele Affects Cognitive Functions Differently in Carriers of APP Mutations Compared to Carriers of PSEN1 Mutations in Autosomal-Dominant Alzheimer’s Disease
por: Almkvist, Ove, et al.
Publicado: (2021)

Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

Gyrification abnormalities in presymptomatic c9orf72 expansion carriers
por: Caverzasi, Eduardo, et al.
Publicado: (2019)

FDG-PET in presymptomatic C9orf72 mutation carriers
por: Popuri, Karteek, et al.
Publicado: (2021)

Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia
por: Poos, Jackie M., et al.
Publicado: (2022)

Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers
por: Dorst, Johannes, et al.
Publicado: (2023)

Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families
por: Cruchaga, Carlos, et al.
Publicado: (2012)

Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2
por: Hsu, Simon, et al.
Publicado: (2020)

Motor Decline in Clinically Presymptomatic Spinocerebellar Ataxia Type 2 Gene Carriers
por: Velázquez-Perez, Luis, et al.
Publicado: (2009)

Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers
por: Lee, Suzee E., et al.
Publicado: (2016)

Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients
por: Kim, Seong Eun, et al.
Publicado: (2020)

COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China
por: Qian, Guoqing, et al.
Publicado: (2020)

Correction: Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families
por: Cruchaga, Carlos, et al.
Publicado: (2012)

PSEN as an Educational Tool in Norway
por: Westvik, Tormod Schumacher
Publicado: (2017)

Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers
por: Ringman, John M., et al.
Publicado: (2012)

Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI
por: Feis, Rogier A., et al.
Publicado: (2018)

Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI
por: Feis, Rogier A., et al.
Publicado: (2019)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Eye movement alterations in presymptomatic C9orf72 expansion gene carriers
por: Behler, Anna, et al.
Publicado: (2021)

White-matter abnormalities in presymptomatic GRN and C9orf72 mutation carriers
por: Lee, Hyunwoo, et al.
Publicado: (2022)

APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease
por: Giau, Vo Van, et al.
Publicado: (2019)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers
por: Olm, Christopher A., et al.
Publicado: (2018)

Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers
por: Clarke, Mica T. M., et al.
Publicado: (2021)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

From EST to structure models for functional inference of APP, BACE1, PSEN1, PSEN2 genes
por: Aathi, Muthusankar, et al.
Publicado: (2019)

APP, PSEN1, and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines
por: Xiao, Xuewen, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5f1c0uo672iditq66ft2o7gnig